A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments.
Alessia Bari,Raffaella Marcheselli,Stefano Sacchi,Alessandro Re,Chiara Pagani,Alessandra Tucci,Barbara Botto,Umberto Vitolo,Anna Lia Molinari,Benedetta Puccini,Alessandro Pulsoni,Armando Santoro,Monica Tani,Luca Nassi,Erika Meli,Vincenzo Pavone,Maurizio Bonfichi,Andrea Evangelista,Daniela Gioia,Alessandro Levis,Pier Luigi Zinzani +20 more
TL;DR: The substantial improvement in survival outcomes in PET2-positive patients treated with early autologous transplantation could explain the complete disappearance of the residual prognostic significance of the International Prognostic Score.
Journal ArticleDOI
Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature
Giulia Burastero,Gabriella Orlando,Armando Santoro,Marianna Menozzi,Erica Franceschini,Andrea Bedini,Adriana Cervo,Matteo Faltoni,Erica Bacca,Emanuela Biagioni,Irene Coloretti,Gabriele Melegari,Jessica Maccieri,Stefano Busani,Elisabetta Bertellini,Massimo Girardis,Giulia Ferrarini,Laura Rofrano,Mario Sarti,Cristina Mussini,Marianna Meschiari +20 more
TL;DR: Despite the high mortality of critically ill COVID-19 patients, CZA, especially in combination therapy, could represent a valid treatment option for VAP due to DTT non-fermenter gram-negative bacteria, including uncommon pathogens such as Burkholderia cepacea and Stenotrophomonas maltophilia.
Journal ArticleDOI
Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
Joel W. Neal,Armando Santoro,Santiago Viteri,Santiago Ponce Aix,Bruno Fang,F.L. Lim,Ryan D. Gentzler,J. Goldschmidt,Polina Khrizman,Erminia Massarelli,Shiven B. Patel,Sonam Puri,R. Sudhagoni,Christian Scheffold,Dominic Curran,Enriqueta Felip +15 more
TL;DR: C + A and C demonstrated encouraging clinical activity with manageable toxicity in pts with aNSCLC previously treated with ICI and platinum-containing chemotherapy in COSMIC-021, a multicenter phase 1b study evaluating C + A in advanced solid tumors.
Journal ArticleDOI
Tivantinib for hepatocellular carcinoma
TL;DR: Clinical data on tivantinib, an oral inhibitor of the hepatocyte growth factor receptor (MET), demonstrated promising antitumor activity in patients with HCC and was reviewed for the second-line treatment of HCC.
Journal ArticleDOI
Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications
Giovanna Masci,Massimo Magagnoli,Vittorio Pedicini,Dario Poretti,Luca Castagna,Carlo Carnaghi,Emanuela Morenghi,Antonietta Del Vecchio,Rita Finotto,Giorgio Brambilla,Armando Santoro +10 more
TL;DR: In this paper, the authors used the Vygon catheter as a long-term CVC in patients with malignancy, and the median duration of catheter use was 93 days, mean 164.3 days (range 1-789).